BP1002
BP1002 is an antisense oligonucleotide targeting BCL-2. BP1002 silences BCL-2 expression by targeting the translation initiation site of Bcl-2 mRNA. Its backbone carries ethoxy modifications, which confer nuclease resistance, reduce off-target effects, and lower toxicity. BP1002 prolongs survival in non-Hodgkin's lymphoma xenograft models. BP1002 can be used in studies of acute myeloid leukemia, aggressive non-Hodgkin's lymphoma, and Venetoclax (HY-15531)-resistant hematological malignancies.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All DNA/RNA Synthesis Isoforms
More
Biological Activity
Description
In Vitro
BP1002 combined with Decitabine (HY-A0004) reduces proliferation of Venetoclax (HY-15531)-resistant leukemic cells by approximately 60%[1].
BP1002 (200 micrograms/mL; 4 days) exhibits cytotoxic activity against multiple human lymphoma cell line subtypes, with ≥50% inhibition observed in the majority of tested GCB DLBCL, all tested ABC DLBCL, the tested MCL, and the tested BL cell lines[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human lymphoma cell lines including germinal center B-cell (GCB) diffuse large B-cell lymphoma (DLBCL), activated B-cell (ABC) DLBCL, mantle cell lymphoma (MCL), and Burkitt's lymphoma (BL) cell lines
-
Concentration:200 μg/mL
-
Incubation Time:4 days
-
Result:Induced ≥50% growth inhibition in 5 of 8 GCB DLBCL cell lines, 3 of 3 ABC DLBCL cell lines, 1 of 1 MCL cell line, and 1 of 1 BL cell line after 4 days of incubation.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Severe combined immunodeficiency (SCID) mice[2]
-
Dosage:10 mg/kg; 20 mg/kg
-
Administration:i.v.; twice per week; initiated 1 week post-implantation
-
Result:Resulted in 0% moribund mice at week 5 at 10 mg/kg and 20 mg/kg in experiment I, while all untreated and control empty liposome-treated mice reached moribund state.
Resulted in 40% moribund mice at week 5 at 20 mg/kg in experiment II, while all untreated and control oligodeoxynucleotide-treated mice were moribund.
Chemical Information
-
SMILES
[BP1002]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
BP1002 Related Classifications
HY-188138 Related Classifications
Powered by Bioz